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The insulin-like growth factor (IGF) system plays an important role in a number of disease states, such as cancer
and psoriasis, through its ability to modulate cell proliferation, attachment, and migration. The type-1 IGF and type-
2 IGF receptors, as well as six IGF-binding proteins (IGFBP-1–6), have well-established roles in mediating IGF
activity. Additionally, it’s been demonstrated that IGF-II binds directly to the extracellular matrix protein vitronectin
(VN), whereas IGF-I does not. IGFBP-5, however, has been recently demonstrated to facilitate the binding of IGF-I to
VN. The aim of this study was to determine whether the interaction between IGF, IGFBP, and VN modulates human
keratinocyte function. Functional assays demonstrated that both the IGF-II:VN and IGF-I:IGFBP-5:VN complexes
resulted in signiﬁcantly enhanced protein synthesis and cell migration through 12 lm pore Transwells in skin
keratinocytes (HaCAT). Furthermore, the IGF-II:VN complex signiﬁcantly enhanced human corneal epithelial (HCE)
cell protein synthesis. Interestingly, the IGF-II:VN complex did not effect either HCE cell migration or attachment.
This is the ﬁrst study to demonstrate a functional role for the interaction between IGF and VN in human
keratinocytes. Moreover, these results suggest that IGF-II:VN and IGF-I:IGFBP-5:VN complexes may be useful in
situations where enhanced keratinocyte cell migration and proliferation is required, such as in wound healing and
skin regeneration.
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Skin growth and repair are highly complex processes that
are tightly regulated through a number of control mechan-
isms. One component that participates in these processes
is the insulin-like growth factor (IGF) family of proteins. This
family consists of two growth factors, IGF-I and IGF-II,
which have a diverse range of biological functions including
growth and development (Wood, 1995), regulation of cell
proliferation and differentiation (Cohick and Clemmons,
1993; Adi et al, 2002) and DNA synthesis (Kiess et al, 1994;
Bach, 1999), as well as insulin-like effects including an
involvement in glucose and fat metabolism (Wood, 1995). In
addition, IGF have been implicated in cell motility due to
their ability to promote actin polymerization at the leading
edge of migrating cells (Leventhal and Feldman, 1997).
IGF-I and IGF-II are in turn regulated by at least two IGF
receptors, six insulin-like growth factor-binding proteins
(IGFBP) (Wood, 1995; Baxter, 2000), and more recently,
although still considered controversial, may also involve a
number of IGFBP-related proteins (Hwa et al, 1999). These
related proteins include connective tissue growth factor
(CTGF) and products from the genes nov, cyr61, and mac25
(Kim et al, 1997). Although the exact functional role of these
related proteins is unclear, it has been suggested that they
may have IGF-independent actions (Rosenfeld et al, 1999).
Upton et al (1999) also discovered that the extracellular
matrix (ECM) protein vitronectin (VN) binds to IGF-II with
an affinity equivalent to that of IGF-II for the type-1 IGF
receptor. Intriguingly, VN is not structurally similar to
‘‘classic’’ IGFBP or IGFBP-related proteins and the study
we report here is one of the first studies to demonstrate the
critical role VN plays in regulating IGF actions.
VN is a multi-functional 75 kDa glycoprotein that is found
in the circulation and numerous tissues and forms a major
component of the ECM (Nogita and Kawashima, 1992). VN
binds to a number of ligands including integrin receptors,
heparin, plasminogen, plasminogen activator inhibitor-1
(PAI-1), thrombin–anti-thrombin (TAT) complexes, glycosa-
minoglycans, collagen, complement, and the urokinase
plasminogen activator receptor (uPAR) (Kost et al, 1992;
Felding-Habermann and Cheresh, 1993; Morris et al, 1994;
Wei et al, 1994; Huang et al, 1998; Francois et al, 1999;
Schvartz et al, 1999). It is via these interactions that VN
plays an important role in diverse cellular processes
including cell migration, cell attachment, cell spreading
and haemostasis. VN is also involved in the immune
defence system through its interaction with the terminal
complex of complement (Kim et al, 1997; Huang et al, 1998;
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Clemmons et al, 1999; Schvartz et al, 1999). More recently
the ability of VN to modify IGF action in smooth muscle cells
(SMC) was highlighted by Clemmons et al (1999) who
reported that blocking VN binding to the integrin avb3
abolishes IGF-I-stimulated responses such as DNA synth-
esis, cell migration, IGFBP-5 production and type-1 IGF
receptor (IGF-IR) autophosphorylation. Subsequent studies
have revealed that IGF-I can bind to VN indirectly via
specific IGFBP and that the presence of IGF-I, IGFBP-5,
and VN results in enhanced functional responses (Nam et al,
2002; Kricker et al, 2003).
Although IGF-II:VN complexes have recently been
reported to stimulate breast cancer cell migration (Noble
et al, 2003), prior to this study there has been no functional
evidence supporting a role for the interaction between VN
and IGF-II in skin. Turchi et al (2002), however, demon-
strated that mechanical injuries in human keratinocytes
immediately stimulated the tyrosine phosphorylation of
numerous cellular proteins and induces molecular cascades
leading to the activation of three distinct MAPK pathways.
These include the extracellular signal-regulated kinases
(ERK), the c-jun-N-terminal protein kinase and the p38
(MAPK) pathway. These findings were supported by
Miyamoto et al (1996), however, they postulated that in
order for these various growth factors to activate the MAPK
pathway, various integrins must be occupied by their
ligands. The activation of the ERK pathway in particular is
believed to have an important role in mediating cell
proliferation in response to various growth factors. These
previous findings, combined with the recent results de-
scribing interactions of IGF and IGFBP with VN, led us to
hypothesize that the interaction between IGF, IGFBP and
VN via their respective receptors (IGF-IR and integrins) is
functionally relevant and may be involved in various cellular
processes including cell motility, proliferation, attachment,
and invasion.
The HaCAT human keratinocyte cell line was chosen for
these studies as it has been shown to exhibit key aspects of
the basal keratinocyte IGF response system and even after
multiple passages these cells retain a remarkable capacity
for normal differentiation and thus offer a suitable and stable
model for keratinocyte studies (Boukamp et al, 1988;
Wraight et al, 2000). Moreover, gaining an understanding
of the interactions of IGF with VN, and its involvement in
skin proliferation, attachment, and migration processes will
help in the development of treatments for wound repair and
other diseases where IGF, IGFBP, and VN have been
implicated and in which modulation of cell proliferation is
required.
The studies reported here demonstrate that the interac-
tion of IGF, IGFBP, and VN is indeed functionally important
as it significantly enhances HaCAT keratinocyte cell
proliferation, migration and cell attachment. The human
corneal epithelial (HCE) cell line was also examined, and
it was determined that the interaction of IGF-II with VN
had similar, although not identical effects. In addition we
adopted the approach of pre-binding IGF and IGFBP to
VN-coated culture dishes such that the effects of IGF bound
to VN were studied, rather than the effects of IGF and
IGFBP in solution. This strategy was adopted in an attempt
to more accurately reflect the environment that cells en-
counter in vivo, in which growth factors ‘‘captured’’ by ECM
proteins participate in coordinated matricellular signalling.
Results
Effects of dimeric IGF:VN complexes on keratinocyte
protein synthesis Since IGF are potent stimulators of
keratinocyte proliferation (Barreca et al, 1992; Liu et al,
1993), we undertook studies examining the ability of the
pre-bound IGF/VN complexes to stimulate protein synth-
esis. This assay has been demonstrated in our laboratory to
correlate with an increase in cell number in HaCAT cells
(unpublished data), therefore can be viewed as an accurate
reflection of cell proliferation, as well as a measure of
protein synthesis. Protein synthesis, expressed as percen-
tage stimulation above control wells, is measured by the
incorporation of [3H]-leucine into newly synthesized protein
over 48 h.
When the wells were exposed to 3, 10, 30, 100, 300 and
1000 ng of IGF-II in the absence of VN, responses of 8%,
12%, 10%, 16%, 24%, and 43% above the control wells,
respectively (-VN, -IGF-II), were observed. But when wells
were exposed to these same doses of IGF-II in the presence
of VN, effects of 19%, 29%, 39%, 51%, 70%, and 101%,
respectively, were obtained. The effect of VN alone in these
experiments was 12%. The values obtained for wells
exposed to IGF-II in the presence of VN, are significantly
different (po0.05) to the effects observed when VN was
absent at all IGF-II amounts except for the two lowest
amounts of IGF-II tested (3 and 10 ng). Thus IGF-II pre-
bound to VN results in significantly enhanced HaCAT
protein synthesis with the effects ranging from 17% to
58% greater than the effects of IGF-II alone (Fig 1A).
In order to determine whether similar effects could also
be obtained when wells were exposed to IGF-I in the
presence of VN, similar experiments were performed with
IGF-I. When wells were exposed to 10, 30, 100, 300, and
1000 ng of IGF-I in the absence of VN, responses of 5%,
5%, 8%, 6%, and 23%, respectively, above the control
wells (-VN, -IGF-I) were observed. When wells were
exposed to these same doses of IGF-I in the presence
of VN responses of 16%, 14%, 20%, 20%, and 42%,
respectively, were obtained. These effects were not
significantly different (po0.05) to the effects of IGF-I alone,
with the exception of the highest amount of IGF-I tested
(1000 ng). The effect of VN alone in this series of
experiments was 7% (Fig 1B).
HaCAT keratinocyte attachment is unaffected by dimeric
IGF:VN complexes Due to VN’s well-established ability to
mediate cell attachment, we examined whether the IGF-
II:VN interaction may alter cell attachment. Thus cell
attachment assays in which IGF-II was pre-bound to VN
in the culture dishes were undertaken in HaCAT cells. When
10, 30, 100, 300, and 1000 ng of IGF-II were exposed to the
wells in the absence of VN, cell attachment of 105%, 96%,
96%, 96%, and 98%, respectively, of that observed in
control wells (-VN, -IGF-II) was obtained. When wells were
exposed to these same doses of IGF-II in the presence of
VN the resulting HaCAT cell attachment was found to be
101%, 99%, 95%, 99%, and 102% of the control wells,
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respectively (Fig 2A). Thus the responses obtained when
IGF-II was bound to VN in the HaCAT cells were not
significantly different (po0.05) to the responses found when
the wells were exposed to IGF-II alone. These results
indicate that the VN:IGF-II complex does not modulate
HaCAT cell attachment. The effect of VN alone in these
experiments was 102% of that observed in control wells.
We also examined HaCAT cell attachment in assays in
which wells were exposed to IGF-I in the presence and
absence of VN. In the absence of VN, exposure of the wells
to 10, 30, 100, 300, and 1000 ng of IGF-I resulted in cell
attachment of 105%, 100%, 101%, 108%, and 115%,
respectively, of that observed in the control wells (-VN, -IGF-
I). When wells were exposed to these same doses of IGF-I
in the presence of VN, cell attachment of 105%, 102%,
102%, 105%, and 112% of the control wells, respectively,
were observed. Thus the effects of IGF-I ‘‘pre-bound’’ to VN
were again not significantly different (po0.05) to the effects
of IGF-I alone (Fig 2B).
Effects of the IGF-II/VN complex on keratinocyte migra-
tion Cell migration is a key process in the metastasis of
tumors and in the wound-healing response; processes
in which both IGF-II and VN have been shown to have
important roles (Campbell et al, 1998). In order to determine
if IGF-II pre-bound to VN stimulates HaCAT cell migration,
the ability of the cells to migrate through a 12 mm Transwell
to the VN:IGF-II pre-treated surface of the lower chamber
was measured.
When 1 mg of VN was pre-bound in the lower chamber of
the Transwells in the absence of IGF-II, migration increased
approximately 5% in HaCATs. Interestingly, when the lower
chamber was pre-exposed to 10 or 100 ng of IGF-II in the
absence of VN, the migration of the HaCAT cells through the
Transwells was slightly inhibited. But when wells were
exposed to 10 or 100 ng of IGF-II in the presence VN in the
lower chamber, the complex stimulated migration that was
37%, 35%, and 73% above the control wells (-VN, -IGF-II),
respectively (Fig 3).
HCE cell protein synthesis is stimulated by the trimeric
IGF-II:VN complex whereas cell attachment and migra-
tion are unaffected As both IGF and VN have been
implicated in human corneal keratinocyte (HCE) cellular
processes including proliferation (Arnold et al, 1993, Sack
et al, 1994), we wished to determine if the IGF-II:VN
complex stimulated HCE protein synthesis. In the absence
of IGF-II, VN alone stimulated a response of 1123% above
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Figure 1
Stimulation of protein synthesis by IGF in the presence and
absence of VN in HaCAT human keratinocytes. The data, expressed
as % stimulation above control (-VN, -IGF-I/II) over 48 h, were pooled
from three replicate experiments in which each treatment was tested in
triplicate. The effects obtained in wells exposed to IGF-II (A) and IGF-I
(B) in the absence of VN (gray bars) are compared with the effects
obtained when the wells were exposed to IGF-II (A) and IGF-I (B) in the
presence of VN (black bars). In all instances, except for the two lowest
concentrations of IGF-II tested, the effect was significantly different ()
(po0.05) to that obtained when VN was absent. For all concentrations
of IGF-I, except for the highest dose tested, the effect was not signi-
ficantly different () (po0.05) to that obtained when VN was absent.
Figure2
Attachment of HaCAT human keratinocytes to culture wells
exposed to IGF in the presence and absence of VN. The data,
expressed as % attachment over 4 h compared with control wells (-VN,
-IGF-I/II), were pooled from three replicate experiments in which each
treatment was tested in triplicate. The effects obtained in wells
exposed to IGF-II (A) and IGF-I (B) alone (gray bars) were compared
with the attachment obtained when wells were exposed to IGF-II (A)
and IGF-I (B) in the presence of VN (black bars). In all instances there
was no significant difference (po0.05) between cell attachment when
the wells were exposed to IGF alone compared with the attachment
obtained when VN was also present.
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the control wells (-VN, -IGF-II). This result most likely
reflects that these cells require the presence of VN to
facilitate attachment to the culture dishes. When wells were
exposed to 30, 100, 300, and 1000 ng of IGF-II in the
absence of VN, responses of 0.5%, 11%, 99%, and 64%
above the control, respectively, were observed, whereas
exposure to 10 ng of IGF-II inhibited proliferation by 10%.
When wells were exposed to these same amounts of IGF-II
in the presence VN, responses of 1353%, 1532%, 1731%,
2204%, and 2062% above the control were observed,
respectively (Fig 4A). All of these responses were signifi-
cantly different (po0.05) to those obtained when VN was
not present, and moreover, were significantly greater than
the responses obtained with VN alone.
In order to confirm whether VN was critical for cell
attachment as hypothesized and to examine whether the
IGF-II:VN complexes effect HCE cell attachment we
conducted assays in which wells were exposed to IGF-II in
the presence or absence of VN. When 10, 30, 100, 300, and
1000 ng of IGF-II were exposed to the wells in the absence
of VN, HCE cell attachments of 98%, 110%, 122%, 141%,
and 137%, respectively, of that obtained in control wells (-
VN, -IGF-II) were observed (Fig 4B). But when the HCE cells
were exposed to these same doses of IGF-II in the presence
of VN, cell attachments of 157%, 170%, 168%, 168%, and
164%, respectively, of that obtained in control wells (-VN, -
IGF-II). Moreover the attachment obtained in the presence of
IGF-II and VN was greater than IGF-II alone. Responses with
IGF-II and VN, however, were not significantly different to VN
alone (Fig 4B). Thus these results differ from the results
obtained with the HaCAT cell line. Indeed, these results
demonstrate that VN is able to modulate HCE cell attach-
ment and further suggests that HCE cells require VN to both
attach (Fig 4B) and proliferate (Fig 4A). In these series of
experiments VN alone, stimulated HCE cell attachment
149% of that observed in control wells (-VN, -IGF-II).
As we have demonstrated that the IGF-II:VN complex
stimulated HCE cell protein synthesis, we wished to
determine whether the IGF-II:VN complex could also
enhance HCE cell migration, hence the ability of the cells
to migrate through 12 mm Transwells to the IGF-II:VN pre-
treated surface of the lower chamber was measured. When
the lower chamber was exposed to 10, 30, 100, and 300 ng
of IGF-II in the absence of VN, the migration of the HCE
cells through the Transwells was not significantly different to
the control (-VN, -IGF-II). But when wells were exposed to
the same doses of IGF-II in the presence VN in the lower
chamber, the complex stimulated HCE cell migration by
135%, 141%, 151%, and 160% above the control wells
(-VN, -IGF-II), respectively (Fig 4C). These responses were
Figure 3
Stimulation of cell migration by IGF-II in the presence or absence
of VN in HaCAT human keratinocytes. The data, expressed as %
stimulation above control (-VN, -IGF-II) over 5 h, were pooled from three
replicate experiments in which each treatment was tested in duplicate.
The effects obtained in wells exposed to IGF-II alone (gray bars) are
compared with the effects obtained when the wells were exposed to
IGF-II in the presence of VN (black bars). For both concentrations
tested there was a significant difference (po0.05) between the pre-
sence or absence of vitronectin ( ), and these effects were significantly
different than the control () or VN alone (#).
Figure4
Stimulation of Human Corneal Epithelial (HCE) protein synthesis,
attachment and migration by IGF-II in the presence or absence of
VN. The data, expressed as % above control wells (-VN, -IGF-II), were
pooled from two replicate experiments in which each treatment was
tested in triplicate. The effects obtained in wells exposed to IGF-II alone
(gray bars) were compared with the effects obtained when wells were
exposed to IGF-II in the presence of VN (black bars) in protein synthesis
(A), attachment (B) and migration (C) assays. Significant difference
(po0.05) between the treatments and the control (), VN alone (#) and
IGF-II alone ( ) are indicated as above.
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significantly different (po0.05) to the responses found when
the wells were exposed to IGF-II alone; however, they were
not significantly different to those obtained with VN alone,
which stimulated cell migration by 41% above the control
(-VN, -IGF-II).
Keratinocyte protein synthesis and migration are sti-
mulated by the trimeric IGF-I:IGFBP-5:VN complex
whereas cell attachment is unaffected As it has pre-
viously been demonstrated that IGFBP-5 facilitates the
binding of IGF-I to VN (Kricker et al, 2003) we examined
whether the IGF-I/IGFBP-5/VN complex stimulated HaCAT
cell protein synthesis. In this series of experiments, all
individual treatments of IGF-I and IGFBP-5 in the presence
or absence of VN, except for 100ng of IGF-I complexed to
VN (94%), were not significantly different to the control wells
(-VN, -IGF-I, -IGFBP-5). When 30 ng of IGF-I and 100 ng of
IGFBP-5 were exposed to the wells in the absence of VN,
protein synthesis increased 200% above the control, with
an increase of 244% above the control observed when VN
was present. If instead 100 ng of IGF-I and 300 ng of
IGFBP-5 were exposed to the wells in the absence of VN,
an increase of 279% above the control was observed. An
increase of 322% above the control was observed when VN
was also present in conjunction with these same amounts of
IGF-I and IGFBP-5 (Fig 5). The responses obtained when
30 ng of IGF-I was bound to VN in the presence of 100 ng
IGFBP-5 were significantly different (po0.05) to the
responses found when the wells were exposed to these
same doses of IGF-I and/or IGFBP-5 alone. There were no
significant differences, however, between the higher doses
of IGF-I and IGFBP-5 tested in the presence or absence of
VN. These results indicate that both the IGF-I:IGFBP-5 and
IGF-I:IGFBP-5:VN complexes modulate HaCAT cell protein
synthesis. The effect of VN alone in this series of experi-
ments was 133% of that observed in control wells.
In order to determine whether the IGF-I/IGFBP-5/VN
complex affected HaCAT cell attachment we conducted
assays in which wells were exposed to IGF-I and IGFBP-5 in
the presence or absence of VN. Unlike the results observed
in the protein synthesis assays all individual treatments of
IGF-I and IGFBP-5 in the presence or absence of VN, were
significantly different to the control wells (-VN, -IGF-I,
-IGFBP-5). In wells exposed to 30 ng of IGF-I and 100 ng
of IGFBP-5 in the absence of VN, cell attachment increased
45% above the control. A similar increase of 37% above the
control was observed when VN was present. Similarly, 100 ng
of IGF-I and 300 ng of IGFBP-5 in the absence of VN led
to increases in cell attachment 34% above the control, and
an increase of 29% above the control when VN was present
(Fig 6). Nevertheless the responses obtained when IGF-I
was bound to VN in the presence of IGFBP-5 were not
significantly different (po0.05) to the responses found when
the wells were exposed to IGF-I and/or IGFBP-5 alone.
These results indicate that the individual treatments of IGF-I
and IGFBP-5, as well as the various complexes, modulate
HaCAT cell attachment. The effect of VN alone in these
experiments was 107% of that observed in control wells.
In order to determine whether the IGF-I:IGFBP-5:VN
complex could also stimulate HaCAT cell migration, the
ability of the cells to migrate through a 12 mm Transwells to
the IGF-I:IGFBP-5:VN pre-treated surface of the lower
chamber was measured. In the absence of VN, 10 ng of
IGF-I inhibited migration by 12% when compared with the
control wells (-VN, -IGF-I, -IGFBP-5). When wells were
exposed to the same amount of IGF-I in the presence of VN,
migration increased by 40%. When 30, 100, and 300 ng of
IGFBP-5 was exposed to the wells in the absence of VN,
migration was inhibited by 5%, 6%, and 8%, respectively,
compared with the control wells. These same amounts of
IGFBP-5, when exposed to the wells in the presence of VN,
resulted in stimulation of migration of 14%, 25%, and 35%,
respectively. When 10 ng of IGF-I and 30 ng of IGFBP-5
were exposed to the wells in the absence of VN cell
migration increased by 28% above the control. An increase
of 251% above the control, however, was observed when
VN was also present. Similarly, exposure of the wells to 10
ng of IGF-I and 100 ng of IGFBP-5 in the absence of VN led
to an increase of 20% above the control was observed,
whereas when VN was present an increase of 285% above
the control was observed (Fig 7). Likewise, wells exposed to
10 ng of IGF-I and 300 ng of IGFBP-5 in the absence of VN,
resulted in an increase of 11% above the control, whereas
these same amounts of IGF-I and IGFBP-5 in the presence
of VN increased cell migration 315% above the control.
Thus the responses obtained when IGF-I was bound to VN
in the presence of IGFBP-5 were significantly different
(po0.05) to the responses found when the wells were
exposed to IGF-I and/or IGFBP-5 alone at all doses tested.
These results indicate that the IGF-I:IGFBP-5:VN complex
modulates HaCAT cell migration. The effect of VN alone in
this series of experiments was 153% of that observed in
control wells.
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Stimulation of protein synthesis by IGF-I and IGFBP-5 in the
presence and absence of VN in HaCAT human keratinocytes. The
data, expressed as % stimulation above control (-VN, -IGF-I, -IGFBP-5)
over 48 h, were pooled from five replicate experiments in which each
treatment was tested in triplicate. The effects obtained in wells
exposed to either IGF-I and/or IGFBP-5 in the absence of VN (gray
bars) were compared with the effects obtained when wells were ex-
posed to IGF-I and/or IGFBP-5 in the presence of VN (black bars). For
all treatments tested there was a significant difference (po0.05) between
the control (), VN alone (#) and the presence or absence of VN ( ).
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Discussion
It was previously reported by Upton et al (1999) that IGF-II
binds to the ECM protein VN, whereas IGF-I does not. Until
very recently, however, no functional roles have been
documented for the interaction of IGF-II with VN. These
recent studies, also performed in our laboratory, demon-
strated that IGF-II bound to VN enhances migration of MCF-7
breast cancer cells (Noble et al, 2003). Interestingly, the
complexes did not affect cell attachment or cell protein
synthesis. The study reported here, using HaCAT keratino-
cytes, found that the IGF-II:VN complex did not effect HaCAT
cell attachment. The IGF-II:VN complex, however, significantly
enhanced protein synthesis and migration in HaCAT cells.
Indeed, the responses to IGF-II:VN complexes are significantly
greater than those obtained with either IGF-II or VN alone.
Although it has been known for some time that IGF-II is
able to stimulate protein or DNA synthesis in a range of
cells, including keratinocytes (Neely et al, 1991), our ap-
proach to these assays was different, and more biologically
relevant. Previous cell culture approaches have added proteins
in solution phase thereby constantly exposing the cells to the
exogenous factors. As solution phase conditions are not
generally present in the environment that cells in tissues
encounter in vivo, we believe that the pre-binding approach
used in this study more accurately reflects the in vivo situation
and thus, the results in this study are more biologically relevant.
Perhaps an explanation for the differences in the effects
of the IGF-II:VN complexes on protein synthesis observed
in MCF-7 cells (Noble et al, 2003) compared with those
observed in the HaCAT keratinocytes studied here resides
in differences in the expression of integrins in these two cell
types. There is increasing evidence that the integrins
themselves act as signaling molecules capable of transdu-
cing messages via classic signaling pathways including the
ERK pathway, thereby modulating cellular functions such as
cellular proliferation (Turchi et al, 2002). As both MCF-7 and
HaCAT cells express avb1 we propose that it may be the
integrin avb6, present in HaCATs but not present in MCF-7s
(Meyer et al, 1998), which plays an important role in cell
proliferation and protein synthesis. In view of the data
obtained we propose that ligand occupancy of avb6 by
VN may enhance cell protein synthesis (Fig 1A) via the
activation of the ERK pathway. When the IGF-II:VN complex
is presented to the cell, however, both the ERK and PI-3
kinase pathways are activated via the coordinate activation
of IGF-IR and avb6, resulting in the significantly enhanced
protein synthesis observed here.
Protein synthesis assays in which IGF-I was ‘‘pre-bound’’
to VN were also performed. Although small increases in cell
protein synthesis were observed as increasing concentra-
tions of IGF-I were added, unlike the responses obtained
with IGF-II, they were not significant (Fig 1B). These results
were not surprising, as IGF-I is unable to bind directly to VN
(Upton et al, 1999). The fact that any responses above the
control wells containing VN alone were observed was
surprising as it was predicted that no IGF-I would remain on
the culture dishes following the pre-binding step. We put
forward two possible explanations for these results. Firstly,
IGFBP, or fragments of these, which are able to mediate the
binding of IGF-I to VN (Kricker et al, 2003), may be present
in the BSA used in the blocking step (Twigg et al, 2000),
therefore facilitating indirect binding of IGF-I to VN.
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Figure 6
Attachment of HaCAT human keratinocytes to culture wells
exposed to IGF-I and IGFBP-5 in the presence and absence of
VN. The data, expressed as % attachment over 4 h compared with
control wells (-VN, -IGF-I, -IGFBP-5), was pooled from two replicate
experiments in which each treatment was tested in triplicate. The
effects obtained in wells exposed to either IGF-I and/or IGFBP-5 and/or
VN (black/gray bars) were compared with the attachment obtained in
the control wells () and VN alone (#) (po0.05). There was no
significant difference, however, between IGF-I and/or IGFBP-5 ex-
posed to VN, and the attachment obtained when VN was not present.
Figure7
Stimulation of cell migration by IGF-I and IGFBP-5 in the presence
and absence of VN in HaCAT human keratinocytes. The data,
expressed as % stimulation above control (-VN, -IGF-I, -IGFBP-5) over
5 h, were pooled from two replicate experiments in which each
treatment was tested in duplicate. The effects obtained in wells
exposed to either IGF-I and/or IGFBP-5 in the absence of VN (gray
bars) were compared with the effects obtained when wells were
exposed to either IGF-I and/or IGFBP-5 in the presence of VN (black
bars). For all treatments tested there was a significant difference
(po0.05) between the control (), VN alone (#) and the presence or
absence of vitronectin ( ).
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Secondly, it has been reported that HaCAT cells express
endogenous IGF-II (Marinaro et al, 1999). Thus the
responses observed may not arise from IGF-I, but may
result from IGF-II secreted by the cells during the experi-
ment, that in turn could bind to the VN bound to the wells,
hence increasing cell proliferation. To confirm the latter
theory further experiments need to be performed in order to
detect and quantitate IGF-II produced by the cells during
the course of the experiment.
As it has previously been demonstrated that IGFBP-5
facilitates the binding of IGF-I to VN (Kricker et al, 2003), we
undertook protein synthesis assays in which IGF-I was
bound to VN in the presence of IGFB-5. Although it was
clearly demonstrated that the IGF-I:IGFBP-5:VN complex
significantly enhanced keratinocyte cell protein synthesis,
the IGF-I:IGFBP-5 complex alone also resulted in enhanced
responses, suggesting that IGFBP-5 may be binding to the
culture-ware plastic and providing a reservoir of IGF-I for
the cells as the ‘‘sticky’’ nature of IGFBP has previously
been reported by various laboratories (unpublished data)
(Fig 5). Although there was a significant difference between
the results observed in the presence of VN compared with
those observed in the absence of VN, these findings
indicate that whereas VN is important in stimulating
keratinocyte protein synthesis it may not be critical. These
findings are in contrast to Nam et al (2002) who demon-
strated that IGF-I:IGFBP-5:VN complexes stimulate SMC
DNA synthesis but if a non-VN binding IGFBP-5 analog was
used, these responses were abolished. It must be noted,
however, that this study utilized a different assay approach.
The cell migration experiments reported here in HaCAT
cells support the recent findings of Noble et al (2003)
demonstrating that the IGF-II:VN complex can stimulate the
migration of MCF-7 breast carcinoma cells. In the HaCAT
study, VN alone was able to slightly stimulate migration
whereas IGF-II alone had little or no effect. Exposure
of wells to IGF-II:VN, however, resulted in significantly
enhanced cell migration (Fig 2). We hypothesize that VN and
the VN-binding integrin receptors present in HaCATs,
primarily the avb6 and avb1 integrins (Huang et al, 1998),
are critical for the migratory response of HaCAT cells in
the presence of IGF-II:VN complexes. This hypothesis is
supported by findings by Jones and Clemmons (1995) who
demonstrated that VN was required for vascular SMC
migration suggesting a VN-binding receptor such as the av-
VN-binding integrins, present on SMC, were required for the
response to IGF. Although there is no direct evidence yet to
support this role for the avb6 and avb1 integrins in HaCAT
cell migration, function-blocking antibodies specifically
directed at these integrins will facilitate elucidation of their
specific role in HaCAT cell migration.
Nam et al (2000) have recently reported that when
IGFBP-5 and IGF-I were added in solution to pre-bound VN,
stimulatory responses are observed in assays measuring
cell migration using the wound scrape assay. If IGFBP-5,
IGF-I, and VN were all added in solution, however, cell
migration from the wound edge was inhibited. Kricker et al
(2003) recently demonstrated that the IGF-I:IGFBP-5:
VN complex bound to culture dishes stimulated MCF-7
cell migration through 12 mm Transwells. Hence, we also
investigated whether the pre-bound complex stimulated
HaCAT cell migration. Unlike the IGF-I:IGFBP-5:VN prolif-
eration assays it was clear that VN is required to stimulate
HaCAT cell migration. Although VN alone significantly
stimulated cell migration above the control (53%), the
IGF-I:IGFBP-5:VN complex increased cell migration 4-fold
(251%) (Fig 7). Interestingly, when IGFBP-5 was complexed
to VN it had an inhibitory effect. This may be due to IGFBP-5
blocking VNs access to its receptors; however, further
studies are required to support this. Nevertheless, the
findings from our migration assays are in concordance with
the results of Clemmons et al (1999) who demonstrated that
blocking the avb3 integrin, a VN-binding integrin, abolished
SMC migration in response to IGF-I.
VN plays a critical role in cell attachment and migration
processes via its interactions with the uPAR and PAI-1
(Deng et al, 1996; Schvartz et al, 1999). Binding of VN to
uPAR stabilizes VN in a conformation that allows the RGD
motif in VN to bind/interact with integrins thereby enabling
cell attachment. Kanse et al (1996) demonstrated that if PAI-
1 instead binds to VN this interaction inhibits binding of VN
to uPAR and in turn inhibits cell attachment and therefore
cell migration. Given the importance of VN in cell attach-
ment, experiments were also undertaken in HaCAT cells to
determine if the IGF-II:VN and IGF-I:IGFBP-5:VN complexes
effect cell attachment. In the assays performed using the
IGF-II:VN complex, no significant differences in cell attach-
ment occurred (Fig 2A), demonstrating that the responses
observed during the protein synthesis assays were not due
to an increase in cell attachment. A similar study was
reported by Reinartz et al (1995), which demonstrated that
HaCAT keratinocytes adhere to VN via the avb5 integrin in a
RGD-dependent manner. Our results demonstrating that
IGF-II:VN complex has no effect on HaCAT cell attachment
suggest that IGF-II when bound to VN does not block or
sterically hinder the RGD-cell binding site in VN. When the
HaCAT cells were exposed to the various IGF-I:IGFBP-5:VN
complexes, however, regardless of the variation of treat-
ments tested, cell attachment was significantly enhanced
(Fig 6). Similar, but not identical findings were reported by
McCaig et al (2002) who demonstrated that IGFBP-5, when
complexed to an ECM gel containing a mixture of proteins,
significantly increased Hs578T breast cancer epithelial cell
attachment. They further reported that IGF-I alone, how-
ever, had little effect and that IGF-I together with IGFBP-5
significantly decreased cell attachment. The findings re-
ported in this study are novel and interesting, and at this
point in time we do not have a comprehensive explanation
for these results.
It has previously been reported that the corneal
epithelium expresses both IGF-IR and the av (VN binding)
integrin chain (Burren et al, 1996; Rayner et al, 1998).
Furthermore, Sack et al (1994) and Arnold et al (1993)
reported that the tear film contains VN and IGF-II. Therefore,
we also investigated whether the IGF-II:VN complex
modifies HCE cell function. Protein synthesis assays were
undertaken, and as was observed with the HaCAT cell
results, it was demonstrated that the IGF-II:VN complex
significantly enhanced HCE cell protein synthesis. Different
results to the HaCAT cells were obtained, however, when
the attachment and migration assays were performed using
the HCEs. Thus cell migration and attachment were
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significantly stimulated above the control (-VN, -IGF-II). The
addition of IGF-II, however, was not greater than that
observed with VN alone. Furthermore, as IGF-II had little or
no effect on HCE cell migration we believe that activation
of the VN receptors alone is the critical element required
to stimulate these migratory and attachment responses in
HCE cells. This highlights the critical importance of VN in
HCE cell function. Clearly, further assays are required to
elucidate why the differing responses are observed in
HaCAT and HCE cell migratory and attachment responses
to IGF-II and VN.
This study represents the first report demonstrating
that both the IGF-II:VN and IGF-I:IGFBP-5:VN complexes
stimulate not only enhanced cell migration, but also
enhanced cell protein synthesis in skin keratinocytes.
Moreover these studies were performed in skin and corneal
epithelial cell lines, rather than in a tumor-derived cell line.
The information gained in this study has provided insights
into the cooperativity of growth factors and ECM proteins in
facilitating keratinocyte cell proliferation and migration.
Furthermore, these results suggest that IGF:VN complexes
may have applications in situations where keratinocyte
proliferation and migration is desirable, such as the treat-
ment of burns or wounds (Turchi et al, 2002). Conversely
IGF:VN complexes antagonists may be useful in situations
where keratinoctye proliferation and migration is not wanted
such as in psoriasis.
Materials and Methods
Cell culture HaCAT human keratinocyte cells, obtained from
Professor Norbet Fusenig (DKFZ, Heidelberg, Germany), were
routinely grown in Dulbecco’s modified eagle medium (DMEM)
(Invitrogen, Mulgrave, Vic., Australia) containing 10% fetal calf
serum (FCS) (Invitrogen). Cells were cultured in 80 cm3 culture
flasks (Nugle Nunc International, Roskilde, Denmark) at 371C, in a
5% CO2 atmosphere. All culture media contained 50 U per mL
penicillin G, 50 mL per mL streptomycin sulfate, and 0.1 mL per mL
gentomycin (Invitrogen) to prevent bacterial growth.
SV40-immortalized HCE cells, obtained from Jason Kasses of
the Cornes and Contact Lens Research Unit (The University of New
South Wales, Sydney, NSW, Australia), were routinely grown in
Dulbecco’s modified eagle medium F-12 (DMEM/F-12) (Invitrogen),
containing 10% FCS (Invitrogen). Cells were cultured in 80 cm2
culture flasks (Nagle Nunc International), at 371C, in a 5% CO2
atmosphere and in the presence of anti-bacterial agents as
described above.
Pre-binding of IGF-I/II and IGFBP-5 to VN In this study a strategy
of pre-binding IGF and IGFBP-5 to VN was used in an attempt to
more accurately reflect the extracellular environment in vivo. Thus,
IGF and IGFBP-5 were pre-bound to VN in 24-well tissue culture
plates and to the lower chamber and membrane surface of 12.0
mM pore Costar Transwells (Costar, New York, New York). This was
achieved by adding 300 mL of serum-free DMEM containing 300 ng
VN (Promega, Annandale, NSW, Australia) to the 24-well plates
(Nagle Nunc International, Roskilde, Denmark) whereas 1 mL of
serum-free DMEM containing 1 mg VN was added to the lower
chamber of the transwells. In both situations the VN-containing
media was incubated for 2 h at 371C. The media containing
unbound VN was then removed by aspiration and each well
washed with 1 mL HEPES binding buffer (HBB) containing 0.5%
bovine serum albumin (BSA) (RIA grade fraction V, Sigma-Aldrich,
Castle Hill, NSW, Australia). Two hundred and fifty mL or 1 mL HBB
containing 0.5% BSA was added to the wells or lower chamber,
respectively, and incubated for 30 min at 371C to reduce non-
specific binding sites on the tissue culture plastic-ware. Following
the removal of this medium, 250 mL or 1 mL of HBB containing
0.5% BSA and IGF-I, IGF-II (GroPep, Adelaide, South Australia,
Australia) or IGFBP-5 (Dr Sue Firth, The University of Sydney,
Sydney, NSW, Australia) was added to the 24-well plates or
Transwells, respectively, and the plates incubated for 2 h at 371C.
The medium was then aspirated and the wells washed with HBB
and air-dried under sterile conditions. Thus only IGF and IGFBP
bound to by the VN were present in the wells.
Protein synthesis assay HaCAT skin keratinocytes or HCE cells
were grown to approximately 80% confluence and then incubated
for 4 h in serum-free DMEM/DMEM-F12, respectively, at 371C. The
cells were trypsinized, diluted in serum-free DMEM/DMEM-F12,
counted and then seeded onto the pre-treated 24-well plates at a
density of 2  105 cells per mL per well or 1  105 cells per mL per
well for the HaCAT or HCE cells, respectively, along with 1 mCi per
well of 3H-leucine (Amersham, Buckinghamshire, UK). The plates
were then incubated for 48 or 40 h, respectively, at 371C. The
medium and any unattached cells were removed and wells were
washed twice with 2 mL Hanks Balanced Salt Solution (Invitrogen),
twice with 2 mL of ice-cold 5% trichloroacetic acid for 5 min each
time and once with 2 mL double distilled H2O (ddH2O). The cell
monolayer was then solubilized in 0.1% triton X-100/0.5 M NaOH
for 1 h. After triturating the cells, 100 mL sub-samples were added
to 5 mL of Ready Safe Scintillation fluid (Beckman, Brea, California)
and counted in a b-Counter LS5000TA liquid scintillation spectro-
meter (Beckman).
Attachment assay HaCAT or HCE cells that were approximately
70% confluent were grown in DMEM/DMEM-F12þ 10% FCS for
18 h in the presence of 2 mCi per mL of 3H-leucine, thus allowing
the incorporation of radioactivity into newly synthesized cell
protein. The cells were then incubated in serum-free DMEM/
DMEM-F12 for 4 h at 371C, 5% CO2. After trypsinization as
described above, cells were counted and 4  105 cells per mL
were added to each well of the pre-treated 24-well culture plates.
Plates were then incubated for 4 h at 371C, 5% CO2 to allow
attachment of cells to the wells. Unattached cells were removed
and wells washed, sub-sampled and counted in the b-counter as
described above.
Migration assay HaCAT human keratinocytes or HCE cells were
routinely passaged in a 1:1 ratio 12–18 h before beginning the
assay (Doerr and Jones, 1996). On the day of the assay the cells
were trypsinized and then seeded into the upper chamber of the
Transwell at a density of 200,000 cells per 200 mL per well in
DMEMþ 0.1% BSA.
The plates were then incubated for 5 h at 371C. The unmigrated
cells in the upper chamber were gently removed using a cotton
swab. Cells which had migrated through the membrane to the
lower chamber were fixed, stained and washed as described in
Leavesley et al (1993). The stain was removed via acid extraction
and the color absorbance was measured. The absorbance has
previously been demonstrated to correlate with the number of cells
which migrate through the membrane (Leavesley et al, 1993).
Statistical analysis In all of the above assays using HaCAT and
HCE cells either duplicate or triplicate treatments were tested and
the entire experiment replicated at least twice. Student t-tests
(p¼ 0.05) were used to determine if there was any significant
difference between the effects of VN alone, IGF alone, IGFBP-5
alone or the IGF-II:VN and IGF-I:IGFBP-5:VN complexes.
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